此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)

2014年4月21日 更新者:Pfizer

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

研究概览

地位

完全的

条件

研究类型

介入性

注册 (实际的)

4740

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aarhus C、丹麦、8000
        • Pfizer Investigational Site
      • Esbjerg、丹麦、6700
        • Pfizer Investigational Site
      • Herlev、丹麦、2730
        • Pfizer Investigational Site
      • Herning、丹麦、7400
        • Pfizer Investigational Site
      • Hilleroed、丹麦、3400
        • Pfizer Investigational Site
      • Koebenhavn OE、丹麦、2100
        • Pfizer Investigational Site
      • Naestved、丹麦、4700
        • Pfizer Investigational Site
      • Roskilde、丹麦、4000
        • Pfizer Investigational Site
      • Vejle、丹麦、7100
        • Pfizer Investigational Site
      • Viborg、丹麦、8800
        • Pfizer Investigational Site
      • Haifa、以色列
        • Pfizer Investigational Site
      • Haifa、以色列、34362
        • Pfizer Investigational Site
      • Jerusalem、以色列、91120
        • Pfizer Investigational Site
      • Jerusalem、以色列
        • Pfizer Investigational Site
      • Kfar Saba、以色列
        • Pfizer Investigational Site
      • Petah Tikva、以色列
        • Pfizer Investigational Site
      • Rehovot、以色列
        • Pfizer Investigational Site
      • St. Petersburg、俄罗斯联邦、197758
        • Pfizer Investigational Site
      • Plovdiv、保加利亚、4004
        • Pfizer Investigational Site
      • Sofia、保加利亚、1756
        • Pfizer Investigational Site
      • Sofia、保加利亚、1504
        • Pfizer Investigational Site
      • Sofia、保加利亚、1784
        • Pfizer Investigational Site
      • Stara Zagora、保加利亚、6003
        • Pfizer Investigational Site
      • Osijek、克罗地亚
        • Pfizer Investigational Site
      • Split、克罗地亚
        • Pfizer Investigational Site
      • Zagreb、克罗地亚、10000
        • Pfizer Investigational Site
      • Zagreb、克罗地亚
        • Pfizer Investigational Site
      • Budapest、匈牙利、1082
        • Pfizer Investigational Site
      • Budapest、匈牙利、1122
        • Pfizer Investigational Site
      • Budapest、匈牙利、1145
        • Pfizer Investigational Site
      • Observatory、南非、7925
        • Pfizer Investigational Site
    • Gauteng
      • Johannesburg、Gauteng、南非、2196
        • Pfizer Investigational Site
      • Luxembourg、卢森堡、1210
        • Pfizer Investigational Site
      • Cairo、埃及
        • Pfizer Investigational Site
      • Belgrade、塞尔维亚、11000
        • Pfizer Investigational Site
      • Sremska Kamenica、塞尔维亚、21204
        • Pfizer Investigational Site
    • Attiki
      • Athens、Attiki、希腊、115 22
        • Pfizer Investigational Site
      • Athens、Attiki、希腊、115 28
        • Pfizer Investigational Site
    • Crete
      • Heraklion、Crete、希腊、71 110
        • Pfizer Investigational Site
      • Berlin、德国、10117
        • Pfizer Investigational Site
      • Berlin、德国、13353
        • Pfizer Investigational Site
      • Chemnitz、德国、09126
        • Pfizer Investigational Site
      • Erlangen、德国、91054
        • Pfizer Investigational Site
      • Freiburg、德国、79106
        • Pfizer Investigational Site
      • Gera、德国、07548
        • Pfizer Investigational Site
      • Greiz、德国、07973
        • Pfizer Investigational Site
      • Halle、德国、06120
        • Pfizer Investigational Site
      • Halle、德国、06110
        • Pfizer Investigational Site
      • Hamburg、德国、22081
        • Pfizer Investigational Site
      • Hildburghausen、德国、98646
        • Pfizer Investigational Site
      • Leipzig、德国、04129
        • Pfizer Investigational Site
      • Luebeck、德国、23538
        • Pfizer Investigational Site
      • Muenchen、德国、80335
        • Pfizer Investigational Site
      • Riesa、德国、01589
        • Pfizer Investigational Site
      • Rodewisch、德国、08228
        • Pfizer Investigational Site
      • Saarbruecken、德国、66113
        • Pfizer Investigational Site
      • Suhl、德国、98527
        • Pfizer Investigational Site
      • Weiden、德国、92637
        • Pfizer Investigational Site
      • Alba (CN)、意大利、12051
        • Pfizer Investigational Site
      • Aviano (PN)、意大利、33081
        • Pfizer Investigational Site
      • Bergamo、意大利、24128
        • Pfizer Investigational Site
      • Biella、意大利、13900
        • Pfizer Investigational Site
      • Cagliari、意大利、09121
        • Pfizer Investigational Site
      • Casale Monferrato, AL、意大利、15033
        • Pfizer Investigational Site
      • Correggio、意大利、42015
        • Pfizer Investigational Site
      • Cremona、意大利、26100
        • Pfizer Investigational Site
      • Cuneo、意大利、12100
        • Pfizer Investigational Site
      • Fermo FM、意大利、63023
        • Pfizer Investigational Site
      • Firenze、意大利、50134
        • Pfizer Investigational Site
      • Genova、意大利、16132
        • Pfizer Investigational Site
      • Genova、意大利、16128
        • Pfizer Investigational Site
      • Lecco、意大利、23900
        • Pfizer Investigational Site
      • Lodi、意大利、20075
        • Pfizer Investigational Site
      • Mantova、意大利、46100
        • Pfizer Investigational Site
      • Milano、意大利、20133
        • Pfizer Investigational Site
      • Milano、意大利、20121
        • Pfizer Investigational Site
      • Milano、意大利、20141
        • Pfizer Investigational Site
      • Milano、意大利、21053
        • Pfizer Investigational Site
      • Modena、意大利、41100
        • Pfizer Investigational Site
      • Monserrato (CA)、意大利、09042
        • Pfizer Investigational Site
      • Monza、意大利、20052
        • Pfizer Investigational Site
      • Napoli、意大利、80131
        • Pfizer Investigational Site
      • Palermo、意大利、90139
        • Pfizer Investigational Site
      • Parma、意大利、43100
        • Pfizer Investigational Site
      • Perugia、意大利、06132
        • Pfizer Investigational Site
      • Piacenza、意大利、29100
        • Pfizer Investigational Site
      • Pietra Ligure (SV)、意大利、17027
        • Pfizer Investigational Site
      • Pisa、意大利、56100
        • Pfizer Investigational Site
      • Reggio Emilia、意大利、42100
        • Pfizer Investigational Site
      • Roma、意大利、00148
        • Pfizer Investigational Site
      • Sassari、意大利、07100
        • Pfizer Investigational Site
      • Terni、意大利、05100
        • Pfizer Investigational Site
      • Thiene (VI)、意大利、36016
        • Pfizer Investigational Site
      • Torino、意大利、10126
        • Pfizer Investigational Site
      • Tortona、意大利、15057
        • Pfizer Investigational Site
      • Trescore Balneario BG、意大利、24069
        • Pfizer Investigational Site
      • Treviglio (BG)、意大利、24047
        • Pfizer Investigational Site
      • Varese、意大利、21100
        • Pfizer Investigational Site
    • Modena
      • Carpi、Modena、意大利、41012
        • Pfizer Investigational Site
      • Bergen、挪威、5021
        • Pfizer Investigational Site
      • Bodo、挪威、8092
        • Pfizer Investigational Site
      • Fredrikstad、挪威、1603
        • Pfizer Investigational Site
      • Haugesund、挪威、5390
        • Pfizer Investigational Site
      • Levanger、挪威、7600
        • Pfizer Investigational Site
      • Mo i Rana、挪威、8607
        • Pfizer Investigational Site
      • Molde、挪威、6407
        • Pfizer Investigational Site
      • Notodden、挪威、3674
        • Pfizer Investigational Site
      • Oslo、挪威
        • Pfizer Investigational Site
      • Rissa、挪威、7100
        • Pfizer Investigational Site
      • Rjukan、挪威、3660
        • Pfizer Investigational Site
      • Sandefjord、挪威
        • Pfizer Investigational Site
      • Tonsberg、挪威、3103
        • Pfizer Investigational Site
      • Tromso、挪威、9038
        • Pfizer Investigational Site
      • Tromsø、挪威、9038
        • Pfizer Investigational Site
      • Brno、捷克共和国、656 53
        • Pfizer Investigational Site
      • Ceske Budejovice、捷克共和国、370 87
        • Pfizer Investigational Site
      • Prague 2、捷克共和国、12808
        • Pfizer Investigational Site
      • Banska Bystrica、斯洛伐克、97517
        • Pfizer Investigational Site
      • Bratislava、斯洛伐克、SK-83310
        • Pfizer Investigational Site
      • Kosice、斯洛伐克、041 90
        • Pfizer Investigational Site
      • Ljubljana、斯洛文尼亚、1000
        • Pfizer Investigational Site
      • Auckland、新西兰、1142
        • Pfizer Investigational Site
    • Waikato
      • Hamilton、Waikato、新西兰、2021
        • Pfizer Investigational Site
      • Antwerpen、比利时、2020
        • Pfizer Investigational Site
      • Arlon、比利时、6700
        • Pfizer Investigational Site
      • Baudour、比利时、7331
        • Pfizer Investigational Site
      • Brasschaat、比利时、2930
        • Pfizer Investigational Site
      • Bruxelles、比利时、1000
        • Pfizer Investigational Site
      • Bruxelles、比利时、1180
        • Pfizer Investigational Site
      • Charleroi、比利时、6000
        • Pfizer Investigational Site
      • Edegem、比利时、2650
        • Pfizer Investigational Site
      • Genk、比利时、3600
        • Pfizer Investigational Site
      • Haine St. Paul、比利时、7100
        • Pfizer Investigational Site
      • Hasselt、比利时、3500
        • Pfizer Investigational Site
      • Kraainem、比利时、1950
        • Pfizer Investigational Site
      • La Louviere、比利时、7100
        • Pfizer Investigational Site
      • Leuven、比利时、3000
        • Pfizer Investigational Site
      • Liege、比利时、4000
        • Pfizer Investigational Site
      • Merksem、比利时、2170
        • Pfizer Investigational Site
      • Namur、比利时、5000
        • Pfizer Investigational Site
      • Verviers、比利时、4800
        • Pfizer Investigational Site
      • Wilrijk、比利时、2610
        • Pfizer Investigational Site
      • Angers、法国、49033 Cedex 01
        • Pfizer Investigational Site
      • Annecy Cedex、法国、74011
        • Pfizer Investigational Site
      • Avignon Cedex 2、法国、84082
        • Pfizer Investigational Site
      • Bordeaux、法国、33030 Cedex
        • Pfizer Investigational Site
      • Bordeaux、法国、33300 Cedex
        • Pfizer Investigational Site
      • Brest、法国、29609 Cedex
        • Pfizer Investigational Site
      • Caen、法国、14052 Cedex
        • Pfizer Investigational Site
      • Caen Cedex 05、法国、14076
        • Pfizer Investigational Site
      • Clermont Ferrand、法国、63011
        • Pfizer Investigational Site
      • Evreux、法国、27000
        • Pfizer Investigational Site
      • Lagny Sur Marne、法国、77405 Cedex
        • Pfizer Investigational Site
      • Le Havre、法国、76600
        • Pfizer Investigational Site
      • Le Mans、法国、72000
        • Pfizer Investigational Site
      • Lille、法国、59020 Cedex
        • Pfizer Investigational Site
      • Lyon、法国、69373
        • Pfizer Investigational Site
      • Marseille、法国、13273
        • Pfizer Investigational Site
      • Meaux、法国、77100
        • Pfizer Investigational Site
      • Montbeliard、法国、25209 Cedex
        • Pfizer Investigational Site
      • Mulhouse、法国、68070 Cedex
        • Pfizer Investigational Site
      • Nice、法国、06189
        • Pfizer Investigational Site
      • Paris、法国、75248 Cedex 5
        • Pfizer Investigational Site
      • Paris、法国、75970 Cedex 20
        • Pfizer Investigational Site
      • Perpignan、法国、66046
        • Pfizer Investigational Site
      • Rennes、法国、35042
        • Pfizer Investigational Site
      • Rouen、法国、76038 Cedex
        • Pfizer Investigational Site
      • Saint-Herblain、法国、44805
        • Pfizer Investigational Site
      • St Cloud、法国、92210
        • Pfizer Investigational Site
      • Strasbourg、法国、67091 Cedex
        • Pfizer Investigational Site
      • Toulouse、法国、31502
        • Pfizer Investigational Site
      • Gdansk、波兰、80-952
        • Pfizer Investigational Site
      • Gliwice、波兰、44-101
        • Pfizer Investigational Site
      • Krakow、波兰、31-115
        • Pfizer Investigational Site
      • Krakow、波兰、31-826
        • Pfizer Investigational Site
      • Lodz、波兰、93-509
        • Pfizer Investigational Site
      • Opole、波兰、45-060
        • Pfizer Investigational Site
      • Poznan、波兰、61-878
        • Pfizer Investigational Site
      • Sopot、波兰、81-756
        • Pfizer Investigational Site
      • Warszawa、波兰、02-781
        • Pfizer Investigational Site
      • Sarajevo、波斯尼亚和黑塞哥维那、71000
        • Pfizer Investigational Site
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
        • Pfizer Investigational Site
      • Dubbo、New South Wales、澳大利亚、2830
        • Pfizer Investigational Site
      • Liverpool、New South Wales、澳大利亚、2170
        • Pfizer Investigational Site
      • Waratah、New South Wales、澳大利亚、2298
        • Pfizer Investigational Site
    • South Australia
      • Adelaide、South Australia、澳大利亚、5000
        • Pfizer Investigational Site
    • Victoria
      • Bendigo、Victoria、澳大利亚、3552
        • Pfizer Investigational Site
      • Box Hill、Victoria、澳大利亚、3128
        • Pfizer Investigational Site
      • Ringwood East、Victoria、澳大利亚、3135
        • Pfizer Investigational Site
      • Cork、爱尔兰
        • Pfizer Investigational Site
      • Cork, Ireland、爱尔兰
        • Pfizer Investigational Site
      • Dublin、爱尔兰
        • Pfizer Investigational Site
      • Dublin 9、爱尔兰
        • Pfizer Investigational Site
      • Galway、爱尔兰
        • Pfizer Investigational Site
      • Tartu、爱沙尼亚、51014
        • Pfizer Investigational Site
      • Boras、瑞典、501 82
        • Pfizer Investigational Site
      • Borås、瑞典、50182
        • Pfizer Investigational Site
      • Goteborg、瑞典、413 45
        • Pfizer Investigational Site
      • Halmstad、瑞典、301 85
        • Pfizer Investigational Site
      • Helsingborg、瑞典、251 87
        • Pfizer Investigational Site
      • Kristianstad、瑞典、291 85
        • Pfizer Investigational Site
      • Linkoping、瑞典、581 85
        • Pfizer Investigational Site
      • Lund、瑞典、221 85
        • Pfizer Investigational Site
      • Malmo、瑞典、205 02
        • Pfizer Investigational Site
      • Motala、瑞典、591 85
        • Pfizer Investigational Site
      • Norrkoping、瑞典、601 82
        • Pfizer Investigational Site
      • Nässjö、瑞典、575 81
        • Pfizer Investigational Site
      • Varnamo、瑞典、331 85
        • Pfizer Investigational Site
      • Vasteras、瑞典、721 89
        • Pfizer Investigational Site
      • Vastervik、瑞典、59381
        • Pfizer Investigational Site
      • Vaxjo、瑞典、351 85
        • Pfizer Investigational Site
      • Basel、瑞士、CH-4031
        • Pfizer Investigational Site
      • Bellinzona、瑞士、CH-6500
        • Pfizer Investigational Site
      • Bern、瑞士、3010
        • Pfizer Investigational Site
      • Bern、瑞士、CH-3012
        • Pfizer Investigational Site
      • Genève、瑞士、CH-1211
        • Pfizer Investigational Site
      • Lima、秘鲁、L34
        • Pfizer Investigational Site
      • Bucuresti、罗马尼亚、72435
        • Pfizer Investigational Site
      • Cluj Napoca、罗马尼亚、400015
        • Pfizer Investigational Site
      • Timisoara、罗马尼亚、300223
        • Pfizer Investigational Site
    • Alabama
      • Birmingham、Alabama、美国、35205
        • Pfizer Investigational Site
      • Birmingham、Alabama、美国、35213
        • Pfizer Investigational Site
      • Birmingham、Alabama、美国、35235
        • Pfizer Investigational Site
    • Arizona
      • Green Valley、Arizona、美国、85614
        • Pfizer Investigational Site
      • Green Velley、Arizona、美国、85614
        • Pfizer Investigational Site
      • Tucson、Arizona、美国、85715
        • Pfizer Investigational Site
      • Tucson、Arizona、美国、85712
        • Pfizer Investigational Site
      • Tucson、Arizona、美国、85710
        • Pfizer Investigational Site
      • Tucson、Arizona、美国、85704
        • Pfizer Investigational Site
      • Tucson、Arizona、美国、85745
        • Pfizer Investigational Site
    • Colorado
      • Boulder、Colorado、美国、80304
        • Pfizer Investigational Site
      • Colorado Springs、Colorado、美国、80909
        • Pfizer Investigational Site
      • Denver、Colorado、美国、80218
        • Pfizer Investigational Site
      • Fort Collins、Colorado、美国、80528
        • Pfizer Investigational Site
      • Lakewood、Colorado、美国、80228
        • Pfizer Investigational Site
      • Thornton、Colorado、美国、80260
        • Pfizer Investigational Site
    • Florida
      • Jacksonville、Florida、美国、32207
        • Pfizer Investigational Site
      • Jacksonville、Florida、美国、32204
        • Pfizer Investigational Site
      • Jacksonville Beach、Florida、美国、32250
        • Pfizer Investigational Site
      • Ocala、Florida、美国、34474
        • Pfizer Investigational Site
      • Orange Park、Florida、美国、32073
        • Pfizer Investigational Site
    • Indiana
      • Fishers、Indiana、美国、46038
        • Pfizer Investigational Site
      • Fishers、Indiana、美国、46037
        • Pfizer Investigational Site
      • Indianapolis、Indiana、美国、46227
        • Pfizer Investigational Site
      • Indianapolis、Indiana、美国、46219
        • Pfizer Investigational Site
      • Indianapolis、Indiana、美国、IN 46219
        • Pfizer Investigational Site
    • Iowa
      • Cedar Rapids、Iowa、美国、52403
        • Pfizer Investigational Site
    • Massachusetts
      • Pittsfield、Massachusetts、美国、01201
        • Pfizer Investigational Site
    • New York
      • Albany、New York、美国、12206
        • Pfizer Investigational Site
      • Latham、New York、美国、12110-0610
        • Pfizer Investigational Site
    • Oregon
      • Portland、Oregon、美国、97225
        • Pfizer Investigational Site
      • Portland、Oregon、美国、97227
        • Pfizer Investigational Site
    • Texas
      • Arlington、Texas、美国、76014-2084
        • Pfizer Investigational Site
      • Bedford、Texas、美国、76022
        • Pfizer Investigational Site
      • Dallas、Texas、美国、75231
        • Pfizer Investigational Site
      • Dallas、Texas、美国、75230-2510
        • Pfizer Investigational Site
      • Dallas、Texas、美国、75246
        • Pfizer Investigational Site
      • El Paso、Texas、美国、79902
        • Pfizer Investigational Site
      • El Paso、Texas、美国、79915
        • Pfizer Investigational Site
      • Garland、Texas、美国、75042
        • Pfizer Investigational Site
      • Houston、Texas、美国、77030
        • Pfizer Investigational Site
      • Houston、Texas、美国、77024
        • Pfizer Investigational Site
      • Houston、Texas、美国、77074
        • Pfizer Investigational Site
      • Houston、Texas、美国、77029
        • Pfizer Investigational Site
      • Longview、Texas、美国、75601
        • Pfizer Investigational Site
      • McAllen、Texas、美国、78503
        • Pfizer Investigational Site
      • Mesquite、Texas、美国、75150
        • Pfizer Investigational Site
      • Odessa、Texas、美国、79761
        • Pfizer Investigational Site
      • Pasadena、Texas、美国、77502
        • Pfizer Investigational Site
      • Plano、Texas、美国、75075-7787
        • Pfizer Investigational Site
      • San Antonio、Texas、美国、78217
        • Pfizer Investigational Site
      • Sherman、Texas、美国、75090
        • Pfizer Investigational Site
      • Sugar Land、Texas、美国、77479
        • Pfizer Investigational Site
      • Tyler、Texas、美国、75702
        • Pfizer Investigational Site
      • Weslaco、Texas、美国、78596
        • Pfizer Investigational Site
    • Washington
      • Spokane、Washington、美国、99202
        • Pfizer Investigational Site
      • Spokane、Washington、美国、99218
        • Pfizer Investigational Site
      • Belfast、英国、BT97AB
        • Pfizer Investigational Site
      • Bradford、英国、BD9 6RJ
        • Pfizer Investigational Site
      • Bristol、英国、BS10 5NB
        • Pfizer Investigational Site
      • Cardiff、英国、CF14 2TL
        • Pfizer Investigational Site
      • Coventry、英国、CV2 2DX
        • Pfizer Investigational Site
      • East Kilbride、英国、G75 8RG
        • Pfizer Investigational Site
      • Huddersfield、英国、HD3 3EA
        • Pfizer Investigational Site
      • Leeds、英国、LS9 7TF
        • Pfizer Investigational Site
      • Leeds、英国、LS1 3EX
        • Pfizer Investigational Site
      • Lincoln、英国
        • Pfizer Investigational Site
      • London、英国、W6 8RF
        • Pfizer Investigational Site
      • London、英国、NW3 2QG
        • Pfizer Investigational Site
      • London、英国、N18 1QX
        • Pfizer Investigational Site
      • London、英国、SW17 0QT
        • Pfizer Investigational Site
      • London、英国、N19 5NF
        • Pfizer Investigational Site
      • Luton、英国、LU4 0DZ
        • Pfizer Investigational Site
      • Manchester、英国、M20 4BX
        • Pfizer Investigational Site
      • Sheffield、英国、S10 2SJ
        • Pfizer Investigational Site
      • Shrewsbury、英国
        • Pfizer Investigational Site
      • Somerset、英国、BA21 4AT
        • Pfizer Investigational Site
      • Southampton、英国、S016 6YD
        • Pfizer Investigational Site
      • Steeton、英国、BD20 6TD
        • Pfizer Investigational Site
      • Stoke on Trent、英国、ST4 6QG
        • Pfizer Investigational Site
      • Telford、英国、TF1 6TF
        • Pfizer Investigational Site
      • Wythenshawe, Manchester、英国、M23 9LT
        • Pfizer Investigational Site
    • Cambs
      • Huntingdon、Cambs、英国、PE18 8NT
        • Pfizer Investigational Site
    • Dorset
      • Bournemouth、Dorset、英国、BH7 7DW
        • Pfizer Investigational Site
    • East Yorkshire
      • Hull、East Yorkshire、英国、HU16 5JQ
        • Pfizer Investigational Site
    • Essex
      • Epping、Essex、英国、CM166TN
        • Pfizer Investigational Site
      • Westcliff-On-Sea、Essex、英国、SS0 0RY
        • Pfizer Investigational Site
    • Gwent
      • Newport、Gwent、英国、NP6 2UB
        • Pfizer Investigational Site
    • Gwynedd
      • Bangor、Gwynedd、英国、LL57 2PW
        • Pfizer Investigational Site
    • Halifax
      • Salterhebble、Halifax、英国、HX6 0PW
        • Pfizer Investigational Site
    • Hants
      • Gosport、Hants、英国、PO12 2AA
        • Pfizer Investigational Site
    • Middlesex
      • Northwood、Middlesex、英国、HA6 2RN
        • Pfizer Investigational Site
    • N. Ireland
      • Londonderry、N. Ireland、英国、BT47 1SB
        • Pfizer Investigational Site
    • N. Yorkshire
      • Harrogate、N. Yorkshire、英国、HG2 7SX
        • Pfizer Investigational Site
    • Somerset
      • Taunton、Somerset、英国、TA1 5DA
        • Pfizer Investigational Site
    • South Wales
      • Swansea、South Wales、英国、SA2 8QA
        • Pfizer Investigational Site
    • Yorkshire
      • York、Yorkshire、英国、Y03 7He
        • Pfizer Investigational Site
      • Amersfoort、荷兰、3818 ES
        • Pfizer Investigational Site
      • Amsterdam、荷兰、1105 AZ
        • Pfizer Investigational Site
      • Amsterdam、荷兰、1066 CX
        • Pfizer Investigational Site
      • Amsterdam、荷兰、1061 AE
        • Pfizer Investigational Site
      • Apeldoorn、荷兰、7300 DS
        • Pfizer Investigational Site
      • Blaricum、荷兰、1261 AN
        • Pfizer Investigational Site
      • Breda、荷兰、4818 CK
        • Pfizer Investigational Site
      • Delft、荷兰、2625 AD
        • Pfizer Investigational Site
      • Den Haag、荷兰、2545 CH
        • Pfizer Investigational Site
      • Eindhoven、荷兰、5623 EJ
        • Pfizer Investigational Site
      • Enschede、荷兰、7513 ER
        • Pfizer Investigational Site
      • Groningen、荷兰、9728 NZ
        • Pfizer Investigational Site
      • Groningen、荷兰、9700 RM
        • Pfizer Investigational Site
      • Hengelo、荷兰、7555 DL
        • Pfizer Investigational Site
      • Leeuwarden、荷兰、8934 AD
        • Pfizer Investigational Site
      • Leiden、荷兰、2333 ZA
        • Pfizer Investigational Site
      • Leidschendam、荷兰、2262 BA
        • Pfizer Investigational Site
      • Podybus 90153、荷兰、5200 ME Den Bosch
        • Pfizer Investigational Site
      • Roermond、荷兰、6043 CV
        • Pfizer Investigational Site
      • Sittard、荷兰、6131 BK
        • Pfizer Investigational Site
      • Utrecht、荷兰、3582 KE
        • Pfizer Investigational Site
      • Veldhoven、荷兰、5504 DB
        • Pfizer Investigational Site
      • Zaandam、荷兰、1502 DV
        • Pfizer Investigational Site
      • Coimbra、葡萄牙、3040
        • Pfizer Investigational Site
      • Coimbra、葡萄牙
        • Pfizer Investigational Site
      • Evora、葡萄牙、7000-811
        • Pfizer Investigational Site
      • Albacete、西班牙、02006
        • Pfizer Investigational Site
      • Alicante、西班牙、03010
        • Pfizer Investigational Site
      • Badajoz、西班牙、06008
        • Pfizer Investigational Site
      • Badajoz、西班牙、06080
        • Pfizer Investigational Site
      • Cordoba、西班牙、14004
        • Pfizer Investigational Site
      • Guadalajara、西班牙、19002
        • Pfizer Investigational Site
      • Lleida、西班牙、25198
        • Pfizer Investigational Site
      • Madrid、西班牙、28034
        • Pfizer Investigational Site
      • Madrid、西班牙、28041
        • Pfizer Investigational Site
      • Madrid、西班牙、28040
        • Pfizer Investigational Site
      • Valencia、西班牙、46014
        • Pfizer Investigational Site
      • Zaragoza、西班牙、50009
        • Pfizer Investigational Site
    • Alicante
      • Alcoy、Alicante、西班牙、03804
        • Pfizer Investigational Site
      • Elche、Alicante、西班牙、03203
        • Pfizer Investigational Site
      • San Juan de Alicante、Alicante、西班牙、03550
        • Pfizer Investigational Site
      • Sant Joan D'Alacant、Alicante、西班牙、03550
        • Pfizer Investigational Site
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • Pfizer Investigational Site
      • Badalona、Barcelona、西班牙、08911
        • Pfizer Investigational Site
      • Terrassa、Barcelona、西班牙、08227
        • Pfizer Investigational Site
      • Terrassa、Barcelona、西班牙、08221
        • Pfizer Investigational Site
    • Guipuzcoa
      • San Sebastian、Guipuzcoa、西班牙、20014
        • Pfizer Investigational Site
    • Huesca
      • Barbastro、Huesca、西班牙、22300
        • Pfizer Investigational Site
    • Tarragona
      • Reus、Tarragona、西班牙、43201
        • Pfizer Investigational Site
      • Buenos Aires、阿根廷、1181
        • Pfizer Investigational Site
      • Cordoba、阿根廷、X5000AA1
        • Pfizer Investigational Site
    • Buenos Aires
      • Haedo、Buenos Aires、阿根廷、1706
        • Pfizer Investigational Site
      • San Isidro、Buenos Aires、阿根廷、1642
        • Pfizer Investigational Site
      • San Martin、Buenos Aires、阿根廷、1650
        • Pfizer Investigational Site
    • Capital Federal
      • Buenos Aires、Capital Federal、阿根廷、1406
        • Pfizer Investigational Site
      • Buenos Aires、Capital Federal、阿根廷
        • Pfizer Investigational Site
      • Buenos Aires、Capital Federal、阿根廷、1426
        • Pfizer Investigational Site
      • Buenos Aires、Capital Federal、阿根廷、1417
        • Pfizer Investigational Site
      • Buenos Aires、Capital Federal、阿根廷、1425
        • Pfizer Investigational Site
    • Pcia. de Santa Fe
      • Rosario 2000、Pcia. de Santa Fe、阿根廷
        • Pfizer Investigational Site
    • Santa Fe
      • Rosario、Santa Fe、阿根廷、2000
        • Pfizer Investigational Site
      • New Territories、香港
        • Pfizer Investigational Site
      • Floriana、马耳他、VLT 14
        • Pfizer Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease

Exclusion Criteria:

  • unresectable breast cancer
  • ER negative primary tumor

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:乙
Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
实验性的:一个
Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study
大体时间:Baseline up to Month 36
DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.
Baseline up to Month 36

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS) at Month 36 Post-Randomization: Main Study
大体时间:Baseline up to Month 120
OS was defined as the duration from randomization to death (due to any cause). OS at Month 36 post-randomization was defined as probability of participants' survival at 36 months after the randomization. For participants who were alive, OS was censored at the last available assessment. Probability of OS at Month 36 post-randomization was reported using Kaplan-Meier estimates at Month 36 post-randomization based on 120-month follow-up data.
Baseline up to Month 120
Number of Events of Second Breast Cancer in Contralateral Breast: Main Study
大体时间:Baseline up to Month 120
Number of events of second primary breast cancer in contralateral breast (excluding ductal carcinoma in situ) were reported.
Baseline up to Month 120
Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
大体时间:Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percent Change From Baseline in Femoral Neck and Femoral Wards Bone Mineral Density (BMD) at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
大体时间:Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for femoral neck (FN) and femoral wards (FW) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) T-scores at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
大体时间:Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. Results were scored as T-score. T-score indicated how many standard deviations higher or lower participant's value was when compared to the young normal reference mean. Using the World Health Organization (WHO) criteria for osteoporosis, a T-score of greater than or equal to (>=)-1.0 was classified as normal, a T-score of greater than -2.5 to less than -1.0 as osteopenic, and a T-score less than or equal to (<=)-2.5 as osteoporotic. Here 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percentage of Bone Specific Alkaline Phosphatase (BAP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Bone specific alkaline phosphatase (BAP) serum concentration analyzed using enzyme immuno assay (EIA) at post-baseline time points was expressed as percentage of baseline BAP serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of C-Terminal Telopeptide (CTX) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
C-terminal telopeptide (CTX) serum concentration analyzed using competitive enzyme-linked immunosorbent assay (ELISA) at post-baseline time points was expressed as percentage of baseline CTX serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Osteocalcin (OC) and Procollagen T1 C-Peptide (PICP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Osteocalcin (OC) serum concentration analyzed using ELISA and procollagen T1 c-peptide (PICP) serum concentration analyzed using sandwich EIA at post-baseline time points was expressed as percentage of baseline OC serum concentration and baseline PICP serum concentration, respectively. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points, for each group respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Deoxy-pyridinoline (DPD) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Deoxy-pyridinoline (DPD) urine concentration (adjusted for urinary creatinine) analyzed using competitive EIA at post-baseline time points was expressed as percentage of baseline DPD urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of N-telopeptide of Type 1 Collagen (NTX) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
N-telopeptide of Type 1 collagen (NTX) urine concentration (adjusted for urinary creatinine) analyzed using competitive inhibition EIA at post-baseline time points was expressed as percentage of baseline NTX urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Number of Participants With Fracture: Bone Metabolism Sub-study
大体时间:Baseline up to 24 months post-treatment
Baseline up to 24 months post-treatment
Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The TOI was defined as the sum of 23 items based on following Functional Assessment of Cancer Therapy - Breast version [FACT-B] subscales: Physical well-being (7 items), Functional well-being (7 items), Breast cancer subscale (9 items). Each item was scaled from 0='Not at all' to 4='Very much'. Total TOI score ranged from 0 to 92, where higher TOI score indicated better health-related quality of life (QoL). A change of five points in the TOI scores was considered clinically meaningful. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. Results for 30, 36, 48, 60 months were not reported because data for these time points was only summarized as graphical presentation.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The FACT-ES assessed health-related QoL in participants with breast cancer. ES subscale comprised of 18 items (hot flushes,cold sweats,night sweats, vaginal discharge,vaginal irritation,vaginal bleeding,vaginal dryness,discomfort with intercourse,lost interest in sex,gained weight,light headed/dizzy,vomiting,had diarrhea,headaches,felt bloated,breast tenderness,mood swings, felt irritable).Participants indicated how true a statement was for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total FACT-ES score was calculated as sum of all the 18 items and ranged from 0 to 72, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
FACT-GBE assessed health-related quality of life (QoL) in participants with breast cancer. It consisted of 56 items,summarized to 7 subscales(subscale 1 to 6 constituted total FACT-B and subscale 7 constituted total ES):physical well-being(7 items), social/family well-being(7 items),relationship with doctor (2 items),emotional well-being(6 items),functional well-being(7 items),breast cancer subscale(9 items),endocrine symptoms(18 items). Participants indicated how true a statement had been for them using 5-point scale from 0(not at all) to 4(very much). For items that were negatively framed,scores were reversed for analysis so that higher scores equated to good QoL. Total FACT-GBE score=sum of all 56 items(range 0 to 224, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The PWB subscale assessed physical well-being related QoL in participants with breast cancer. PWB subscale comprised of 7 items (energy lack, nausea, family needs, pain, side effects, felt ill, forced to stay in bed). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total PWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better physical well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The SWB subscale assessed social/family well-being related QoL in participants with breast cancer. SWB subscale comprised of 7 items (distant from friends, emotional support, support from friends, family acceptance, family communication, close to main support, sexual satisfaction). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total SWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better social/family well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The RWD subscale assessed relationship with doctor in participants with breast cancer. RWD subscale comprised of 2 items (confidence in doctors, doctor answered questions). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total RWD score was calculated as the sum of the 2 items and ranged from 0 to 8, where higher score indicated better relationship with doctor. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The EWB subscale assessed emotional well-being related QoL in participants with breast cancer. EWB subscale comprised of 6 items (felt sad, proud of coping, lost hope, felt nervous, worried about dying, worried about condition worsening). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equate to a good QoL. Total EWB score was calculated as the sum of the 6 items and ranged from 0 to 24, where higher score indicated better emotional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The FWB subscale assessed functional well-being related QoL in participants with breast cancer. FWB subscale comprised of 7 items (able to work, work fulfilled, able to enjoy life, acceptance of illness, sleeping well, enjoyed normal fun activities, contented with QoL). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total FWB score was calculated as the sum of the 7 items and ranged from 0 to 28, where higher score indicated better functional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
大体时间:Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The BCS subscale assessed health related QoL in participants with breast cancer. BCS subscale comprised of 9 items (short of breath, self-conscious dress, tender/swollen arms, sexually attractive, bothered by hair loss, worried about familial risk, worried about family stress, bothered by weight change, able to feel like a woman). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total BCS score was calculated as the sum of the 9 items and ranged from 0 to 36, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Number of Participants With Severe Endocrine Symptoms: QoL Sub-study
大体时间:Baseline up to 24 months after randomization
Participants indicated prevalence of an endocrine subscale items using a 5-point scale, where 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). Endocrine items were grouped in five categories vasomotor (hot flushes, cold sweats, night sweats, sleeping difficulties), neuropsychological (lack of energy, nervous feeling, lightheaded/dizzy, headaches, mood swings, feeling irritable), gastrointestinal symptoms (nausea, gained weight, vomiting, diarrhea, bloated feeling), gynecological symptoms (vaginal discharge, vaginal irritation, vaginal bleeding, vaginal dryness, discomfort with intercourse, lost interest in sex, breast tenderness) and other symptoms (pain, feeling ill, side effects). Number of participants who reported severe endocrine symptoms (defined as response categories "quite a bit" and "very much") were presented.
Baseline up to 24 months after randomization
Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study
大体时间:6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial thickness was assessed using transvaginal ultrasound examination. 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial Thickness: Endometrial Sub-study
大体时间:Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial thickness was assessed using transvaginal ultrasound examination. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Uterine and Overall Ovary Volume: Endometrial Sub-study
大体时间:6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Uterine volume (UV) and ovarian volume was estimated using ultrasonography. Uterine volume = (longitudinal diameter * transverse diameter * anteroposterior diameter of uterus)/(2*1000). Ovary volume = [(longitudinal diameter * transverse diameter * anteroposterior diameter of ovary) * 3.14]/(6*1000). Overall ovary volume (OV) is calculated as the sum of the right and left ovary volume. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Number of Participants With Polyps, Fibroids and Ovarian Cysts: Endometrial Sub-study
大体时间:6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Number of participants with presence of polyps (POL) and fibroids (FIB) at post-baseline time points compared to the baseline (BL) status of 'yes', 'no' or 'missing' (that is, participants reporting POL/FIB at post-baseline time points who had yes, no or missing POL/FIB status at baseline, respectively) were presented. Result for number of participants with ovarian cysts was not analyzed at post-baseline time points as very few participants reported ovarian cysts at baseline.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Percentage of Participants With at Least 1 Gynecological Symptoms: Endometrial Sub-study
大体时间:Baseline up to 24 months post-treatment
Gynecological symptoms included bleeding/spotting, pelvic pain, leucorrhoea and vaginal itching.
Baseline up to 24 months post-treatment
Number of Participants With Histological Findings: Endometrial Sub-study
大体时间:Baseline up to 24 months post-treatment
Baseline up to 24 months post-treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

1998年2月1日

初级完成 (实际的)

2003年6月1日

研究完成 (实际的)

2013年3月1日

研究注册日期

首次提交

2002年5月31日

首先提交符合 QC 标准的

2002年5月31日

首次发布 (估计)

2002年6月3日

研究记录更新

最后更新发布 (估计)

2014年5月7日

上次提交的符合 QC 标准的更新

2014年4月21日

最后验证

2014年4月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅